ASH 2018 highlights in myeloma
Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in…
Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in…
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States)…
Data from the phase III MAIA clinical trial was presented yesterday as part of the Late-Breaking Abstracts Session during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego.
Initial data from the ongoing phase I clinical trial of bb21217 (CRB-402) were presented at the 60th Annual Meeting of the American Society of Hematology (ASH). This is an investigational next-generation anti-BCMA CAR T cell…
The annual meeting of the American Society of Haematology (ASH) 2018 starts this week (between 1 and 4 December) in San Diego, California.
At the recent European Haematology Association (EHA) Annual Congress 2018, Myeloma Patients Europe (MPE) and Video Journal of Hematological Oncology (VJHemOnc), filmed an interview with Dr Michael Hudecek (University of Würzburg, Germany) on the Horizon2020…
A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North America, according to the announcement the European…
At the recent European Haematology Association (EHA) Annual Congress 2018, Myeloma Patients Europe (MPE) and Video Journal of Hematological Oncology (VJHemOnc), filmed an interview with Dr Michael Hudecek (University of Würzburg, Germany) on the Horizon2020…